Acadia Pharma (ACAD) Misses Q1 EPS by 7c, Revs Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
May 1, 2019 4:05 PM EDT
- 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18
-
Updated 2019 Net Sales Guidance to $280 Million to $300 Million
-
Completed Enrollment in Two Late-Stage Adjunctive Schizophrenia Studies
with Pimavanserin
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the first quarter ended March 31, 2019.
Weve commenced 2019 with significant momentum. The... More
